Cogent Biosciences (NASDAQ:COGT – Get Free Report) had its target price raised by Citigroup from $13.00 to $15.00 in a research report issued to clients and investors on Tuesday, Benzinga reports. The firm presently has a “buy” rating on the technology company’s stock. Citigroup’s price target would indicate a potential upside of 39.02% from the stock’s previous close.
Other equities analysts have also recently issued research reports about the company. Needham & Company LLC reiterated a “buy” rating and set a $18.00 target price on shares of Cogent Biosciences in a report on Wednesday, August 7th. Wedbush restated a “neutral” rating and set a $11.00 price objective (up from $10.00) on shares of Cogent Biosciences in a research note on Tuesday, September 3rd. JPMorgan Chase & Co. lowered their price target on Cogent Biosciences from $22.00 to $19.00 and set an “overweight” rating on the stock in a research report on Wednesday, August 7th. HC Wainwright cut their price objective on Cogent Biosciences from $19.00 to $17.00 and set a “buy” rating for the company in a research report on Tuesday, September 3rd. Finally, Robert W. Baird boosted their target price on Cogent Biosciences from $8.00 to $10.00 and gave the stock a “neutral” rating in a report on Thursday, September 5th. Two research analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $15.00.
Check Out Our Latest Stock Analysis on Cogent Biosciences
Cogent Biosciences Price Performance
Cogent Biosciences (NASDAQ:COGT – Get Free Report) last announced its quarterly earnings results on Tuesday, August 6th. The technology company reported ($0.59) EPS for the quarter, missing analysts’ consensus estimates of ($0.56) by ($0.03). During the same quarter in the prior year, the company earned ($0.59) earnings per share. On average, research analysts expect that Cogent Biosciences will post -2.25 earnings per share for the current fiscal year.
Institutional Inflows and Outflows
Institutional investors have recently modified their holdings of the stock. Jump Financial LLC bought a new stake in Cogent Biosciences during the 4th quarter worth approximately $147,000. Dynamic Technology Lab Private Ltd acquired a new stake in Cogent Biosciences in the fourth quarter valued at $70,000. Trexquant Investment LP raised its position in Cogent Biosciences by 88.3% during the 4th quarter. Trexquant Investment LP now owns 77,402 shares of the technology company’s stock worth $455,000 after purchasing an additional 36,294 shares during the last quarter. Capstone Investment Advisors LLC acquired a new position in Cogent Biosciences during the 4th quarter worth about $238,000. Finally, NEOS Investment Management LLC bought a new stake in shares of Cogent Biosciences in the 4th quarter valued at about $76,000.
Cogent Biosciences Company Profile
Cogent Biosciences, Inc, a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes bezuclastinib (CGT9486), a selective tyrosine kinase inhibitor designed to target mutations within the KIT receptor tyrosine kinase, including KIT D816V KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors.
Featured Articles
- Five stocks we like better than Cogent Biosciences
- Transportation Stocks Investing
- Biohaven Stock Soars on Drug Trial Results: Time to Jump In?
- 3 Grocery Stocks That Can Help Take a Bite Out of Inflation
- Is AMD a Legitimate Threat to NVIDIA? What Investors Should Watch
- Dividend Payout Ratio Calculator
- Novo Nordisk’s Setback Won’t Last: A Game-Changing Drug Emerges
Receive News & Ratings for Cogent Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cogent Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.